RU2012125827A - Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции - Google Patents
Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции Download PDFInfo
- Publication number
- RU2012125827A RU2012125827A RU2012125827/15A RU2012125827A RU2012125827A RU 2012125827 A RU2012125827 A RU 2012125827A RU 2012125827/15 A RU2012125827/15 A RU 2012125827/15A RU 2012125827 A RU2012125827 A RU 2012125827A RU 2012125827 A RU2012125827 A RU 2012125827A
- Authority
- RU
- Russia
- Prior art keywords
- ht1a
- testosterone
- analogue
- testosterone analogue
- sexual dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Abstract
1. Применение аналога тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час и указанный аналог тестостерона - за 3,5-5,5 часов до сексуальной активности.2. Применение аналога тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час, указанный ингибитор ФДЭ5 за 1-2 ч и указанный аналог тестостерона - за 3,5-5,5 ч до сексуальной активности.3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.4. Фармацевтическая композиция, включающая аналог тестостерона и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.5. Фармацевтическая композиция, включающая аналог тестостерона, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, включающую аналог тестостерона и, по меньшей мере, одну композицию, включающую агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает аналог тестостерона, по меньшей мере, одну фармацевтическую композици�
Claims (8)
1. Применение аналога тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час и указанный аналог тестостерона - за 3,5-5,5 часов до сексуальной активности.
2. Применение аналога тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час, указанный ингибитор ФДЭ5 за 1-2 ч и указанный аналог тестостерона - за 3,5-5,5 ч до сексуальной активности.
3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.
4. Фармацевтическая композиция, включающая аналог тестостерона и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.
5. Фармацевтическая композиция, включающая аналог тестостерона, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.
6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, включающую аналог тестостерона и, по меньшей мере, одну композицию, включающую агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает аналог тестостерона, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5, и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
8. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой мужскую сексуальную дисфункцию.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976.7 | 2006-11-03 | ||
| EP06076976A EP1925307A1 (en) | 2006-11-03 | 2006-11-03 | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120990/15A Division RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012125827A true RU2012125827A (ru) | 2013-12-27 |
| RU2646447C2 RU2646447C2 (ru) | 2018-03-05 |
Family
ID=37846101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US8653051B2 (ru) |
| EP (5) | EP1925307A1 (ru) |
| JP (8) | JP2010509211A (ru) |
| KR (6) | KR20090115113A (ru) |
| CN (6) | CN104524580A (ru) |
| AU (3) | AU2007314735B2 (ru) |
| BR (3) | BRPI0717963A2 (ru) |
| CA (3) | CA2668317C (ru) |
| CY (1) | CY1117191T1 (ru) |
| DK (1) | DK2086544T3 (ru) |
| ES (1) | ES2561946T3 (ru) |
| HK (1) | HK1135038A1 (ru) |
| HR (1) | HRP20160108T1 (ru) |
| HU (1) | HUE026752T2 (ru) |
| IL (5) | IL198460A (ru) |
| ME (1) | ME02410B (ru) |
| MX (3) | MX2009004696A (ru) |
| NO (3) | NO343597B1 (ru) |
| NZ (3) | NZ577390A (ru) |
| PH (2) | PH12014501440A1 (ru) |
| PL (1) | PL2086544T3 (ru) |
| PT (1) | PT2086544E (ru) |
| RS (1) | RS54541B1 (ru) |
| RU (4) | RU2491073C2 (ru) |
| SI (1) | SI2086544T1 (ru) |
| UA (4) | UA103592C2 (ru) |
| WO (3) | WO2008054215A2 (ru) |
| ZA (3) | ZA200903835B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2436579C2 (ru) | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| KR102158948B1 (ko) * | 2011-05-13 | 2020-09-24 | 이비 아이피 하이브리탭스 비.브이. | 약물 전달 시스템 |
| HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| US10471514B2 (en) | 2014-02-21 | 2019-11-12 | Kochi University, National University Corporation | Method for producing nickel powder |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) * | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| DK169601B1 (da) * | 1983-10-17 | 1994-12-19 | Duphar Int Res | Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) * | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| US6174890B1 (en) | 1994-06-02 | 2001-01-16 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| CZ278497A3 (cs) | 1995-03-14 | 1998-04-15 | Vivus, Incorporated | Způsob a sestava zařízení k prevenci impotence |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| CA2219082A1 (en) | 1995-05-15 | 1996-11-21 | Beth Israel Deaconess Medical Center, Inc. | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| AU756136B2 (en) * | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ， エルエルシー | 女性の性的機能不全の処置 |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) * | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (ru) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ |
| EP1173167A4 (en) | 1999-04-30 | 2004-07-14 | Lilly Icos Llc | TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| CA2377339A1 (en) | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | Administration of growth hormone (hgh) for the therapy of sexual functional disorders |
| RU2180591C2 (ru) | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) * | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| CN1473047A (zh) | 2000-08-30 | 2004-02-04 | ������ҩ������˾ | 治疗男性勃起功能障碍和增强性冲动的方法 |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| SK287066B6 (sk) | 2000-09-29 | 2009-11-05 | Solvay Pharmaceuticals B. V. | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
| US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| JP2004522720A (ja) * | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| EP1383502A4 (en) | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER |
| EA006154B1 (ru) | 2001-03-28 | 2005-10-27 | Пфайзер Инк. | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| JP2007516949A (ja) * | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| ES2258694T3 (es) * | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| RU2445095C2 (ru) | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
| RU2436579C2 (ru) * | 2004-05-11 | 2011-12-20 | Эмоушнл Брэйн Б.В. | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции |
| KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
| WO2006127057A1 (en) * | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| KR101694551B1 (ko) | 2007-11-28 | 2017-01-09 | 유씨비 파마 게엠베하 | 로티고틴의 다형 형태 |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/en not_active Ceased
-
2007
- 2007-02-11 UA UAA200905653A patent/UA103592C2/ru unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/ru unknown
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/me unknown
- 2007-02-11 UA UAA200905652A patent/UA100119C2/ru unknown
- 2007-11-02 EP EP07834664A patent/EP2086545A2/en not_active Withdrawn
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Application Discontinuation
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko active Application Filing
- 2007-11-02 RS RS20160069A patent/RS54541B1/en unknown
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/en not_active Withdrawn
- 2007-11-02 EP EP07834665A patent/EP2086548A2/en not_active Withdrawn
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/en active Active
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/en active Application Filing
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/en active Application Filing
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 CA CA2668317A patent/CA2668317C/en not_active Expired - Fee Related
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 CA CA2668320A patent/CA2668320C/en not_active Expired - Fee Related
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko active IP Right Grant
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko active Application Filing
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko active IP Right Grant
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/en active Application Filing
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 CA CA2668316A patent/CA2668316C/en active Active
- 2007-11-02 US US12/513,358 patent/US8575139B2/en active Active
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Application Discontinuation
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
-
2009
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HK HK10103442.6A patent/HK1135038A1/xx not_active IP Right Cessation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821B1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-01 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| HK1147098A1 (en) | Deuterated etravirine | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| RS51563B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| EA200601654A1 (ru) | Ингибиторы интегразы вич | |
| RS52922B (en) | PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| SV2008002612A (es) | Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| AR074214A1 (es) | Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica | |
| PA8586301A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| DE602004019528D1 (de) | Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
| HK1131340A1 (en) | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance | |
| HRP20080255A2 (en) | Use of cicletanine and other furopyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| CL2008002223A1 (es) | Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201103 |